Watch Total Prescribing Facts OPDIVO® (nivolumab) is indicated to the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or right after 3 or more strains of systemic therapy that features autologous HSCT.Hyperb